Primary-progressive multiple sclerosis

@article{Miller2007PrimaryprogressiveMS,
  title={Primary-progressive multiple sclerosis},
  author={D. Miller and S. Leary},
  journal={The Lancet Neurology},
  year={2007},
  volume={6},
  pages={903-912}
}
  • D. Miller, S. Leary
  • Published 2007
  • Medicine
  • The Lancet Neurology
  • About 10-15% of patients with multiple sclerosis (MS) present with gradually increasing neurological disability, a disorder known as primary-progressive multiple sclerosis (PPMS). Compared with relapse-onset multiple sclerosis, people with PPMS are older at onset and a higher proportion are men. Inflammatory white-matter lesions are less evident but diffuse axonal loss and microglial activation are seen in healthy-looking white matter, in addition to cortical demyelination, and quantitative MRI… CONTINUE READING
    295 Citations
    The role of advanced magnetic resonance imaging techniques in primary progressive MS
    • 22
    • Highly Influenced
    Clinical and MRI features of primary progressive multiple sclerosis
    • PDF
    Innate immunity in progressive multiple sclerosis
    Diagnostic modalities in multiple sclerosis: Perspectives in children
    • 9
    • PDF
    Meningeal inflammation plays a role in the pathology of primary progressive multiple sclerosis.
    • 241
    • PDF
    Secondary Progressive Multiple Sclerosis: Definition and Measurement
    • 23
    • Highly Influenced
    • PDF

    References

    SHOWING 1-10 OF 198 REFERENCES
    Cord atrophy separates early primary progressive and relapsing remitting multiple sclerosis
    • 69
    Natural history of multiple sclerosis
    • 176
    Primary progressive multiple sclerosis: a 5-year clinical and MR study.
    • 118
    • PDF
    The normal appearing grey matter in primary progressive multiple sclerosis
    • 115
    Cortical demyelination and diffuse white matter injury in multiple sclerosis.
    • 1,437
    • PDF
    Axonal damage in acute multiple sclerosis lesions.
    • 1,474
    • PDF
    Multiple sclerosis: current and future treatment options.
    • S. Rizvi
    • Medicine
    • Endocrine, metabolic & immune disorders drug targets
    • 2007
    • 26